Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone

Journal of Clinical Psychopharmacology

Volumn 17, Issue 4, 1997, Pages 308-313

  Kopala, Lili C ^a,c   Good, Kimberley P ^b   Honer, William G ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; LORAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030759369     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199708000-00011     Document Type: Article

References (22)

1. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
3. Kopala L, Fredrikson D, Good KP, Honer WG. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol Psychiatry 1996;39:296-8.
4. Caligiuri MP, Lohr JB, Jeste DV. Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 1993;150:1343-8.
5. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenia patients. Am J Psychiatry 1995; 152:1724-9.
6. Aguilar EJ, Matcheri SK, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994;151: 1819-21.
7. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233.
8. Hafner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, van der Heiden W. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res 1992;6:209-23.
9. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 1987; 13:261-75.
10. Guy W. ECDEU assessment manual for psychopharmacology, rev ed Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare, 1976; Publication ADM 76-338.
11. Oldfield RC. The assessment and analysis of handedness. The Edinburgh Inventory. Neuropsychologia 1971;9:97-113.
12. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-9.
13. Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: E&S Livingstone, 1919.
14. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992;28:81-6.
15. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990;16:185-94.
16. Lieberman J, Alvir JMJ, Woerner M, Degreef G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler H, Loebel A, Levy DL, Hinrichsen G, Szymanski S, Chakos M, Koreen A, Borensteln M, Kane JM. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992;18:51-69.
17. 2 receptor occupancy studies and clinical response. Br J Psychiatry 1996; 168[suppl]:40S-44S.
18. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57: 103-7.
19. 2 receptor in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15[suppl 1]:19S-23S.
20. Gallhofer B, Bauer U, Gruppe H, Krieger S, Lis S. First episode schizophrenia; the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 1996;2[suppl]:16S-24S.
21. Chouinard G, Aimable L, Ross-Chouinard A, Mercier P. A five year prospective longitudinal study of dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8[suppl]: 21S-26S.
22. Jeste DV, Caligiuri MP, Paulsen JS. Risk of tardive dyskinesia in older patients. Arch Gen Psychiatry 1995;52:756-65.